Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: A four arms phase Ib study

Annals of Oncology

Volumn 27, Issue 12, 2016, Pages 2242-2250

  Kanda, Shintaro ^a   Goto, K ^a   Shiraishi, H ^a   Kubo, E ^a   Tanaka, A ^a   Utsumi, H ^a   Sunami, K ^a   Kitazono, S ^a   Mizugaki, H ^a   Horinouchi, H ^a   Fujiwara, Y ^a   Nokihara, H ^a   Yamamoto, N ^a   Hozumi, H ^b   Tamura, T ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Chemotherapy; Combination; Nivolumab; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NIVOLUMAB; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; MONOCLONAL ANTIBODY; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DRY SKIN; EPISTAXIS; ERYTHEMA MULTIFORME; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEARING IMPAIRMENT; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOPHYSITIS; HYPOTHYROIDISM; HYPOXIA; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; LUNG INFECTION; MAINTENANCE THERAPY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; STOMATITIS; THYROID DISEASE; TREATMENT DURATION; TREATMENT INDICATION; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PEMETREXED; TAXOIDS;

EID: 85015412706     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw416     Document Type: Article

References (19)

1. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550
2. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551
3. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103
4. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454
5. Yamamoto N, Yamada Y, Nokihara H et al. Phase I study of ONO-4538 (BMS-936558), an anti PD-1 antibody, in Japanese patients with advanced solid tumors. Ann Oncol 2012; 23: ix152-ix174
6. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135
7. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639
8. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002; 62: 2353-2358
9. Kodumudi KN, Woan K, Gilvary DL et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010; 16: 4583-4594
10. Hato SV, Khong A, de Vries IJ et al. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 2014; 20: 2831-2837
11. Roland CL, Lynn KD, Toombs JE et al. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009; 4: e7669
12. Shrimali RK, Yu Z, Theoret MR et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-6180
13. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175
14. Kawano Y, Ohyanagi F, Yanagitani N et al. Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study. Anticancer Res 2013; 33: 3327-3333
15. Niho S, Kunitoh H, Nokihara H et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012; 76: 362-367
16. Kawaguchi T, Ando M, Asami K et al. Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902-1908
17. Nishino M, Sholl LM, Hodi FS et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373: 288-290
18. Weber JS, Anotnia SJ, Topalian SL et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J Clin Oncol 2015; 33(Suppl): 9018
19. Rizvi NA, Hellmann MD, Brahmer JR et al. Nivolumab in combination with platinumbased doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016: JCO669861